Neuronetics Investor Relations Material
Latest events
Q2 2025
Neuronetics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neuronetics Inc
Access all reports
Neuronetics Inc develops and markets non-invasive neurostimulation therapies for mental health disorders. The company’s primary product is a transcranial magnetic stimulation system used in the treatment of major depressive disorder and other psychiatric conditions. It serves healthcare providers in the United States. The company is headquartered in Malvern, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for Neuronetics Inc
Q2 2025
Neuronetics Inc
Q2 2025
Neuronetics Inc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
STIM
Country
🇺🇸 United States